Skip to main content
. 2024 Feb 13;30(3):716–729. doi: 10.1038/s41591-024-02808-y

Extended Data Fig. 1. PFS and OS by treatment cohort.

Extended Data Fig. 1

PFS and OS with a, b, durvalumab-ceralasertib (median OS not yet mature in ATM biomarker-matched cohort), c, d, durvalumab-olaparib, e, f, durvalumab-danvatirsen, g, h, durvalumab-oleclumab.